OBJECTIVES: Human papillomavirus (HPV) infection is a major risk factor for cervical cancer. Imiquimod is a topical medication that enhances the immune response to HPV-induced genital warts. This study evaluated cervical application of imiquimod as an adjunct to standard treatment for cervical dysplasia. STUDY DESIGN:Fifty-six patients were randomized to standard excisional/ablative treatment vs applications of imiquimod followed by standard treatment. The primary endpoint was dysplasia recurrence within 2 years. RESULTS: There were no differences in dysplasia recurrence between the 2 groups. Treatment was well tolerated, with side effects being mild but significantly worse in women receiving imiquimod for, chills, fatigue, fever, headache, myalgias, and vaginal discharge. CONCLUSION: This trial does not support the hypothesis that imiquimod, as used in this trial, has an impact on recurrence of cervical dysplasia, but the adequacy of findings are limited by sample size. The trial does support the feasibility and acceptability of the use of imiquimod on the cervix.
RCT Entities:
OBJECTIVES:Humanpapillomavirus (HPV) infection is a major risk factor for cervical cancer. Imiquimod is a topical medication that enhances the immune response to HPV-induced genital warts. This study evaluated cervical application of imiquimod as an adjunct to standard treatment for cervical dysplasia. STUDY DESIGN: Fifty-six patients were randomized to standard excisional/ablative treatment vs applications of imiquimod followed by standard treatment. The primary endpoint was dysplasia recurrence within 2 years. RESULTS: There were no differences in dysplasia recurrence between the 2 groups. Treatment was well tolerated, with side effects being mild but significantly worse in women receiving imiquimod for, chills, fatigue, fever, headache, myalgias, and vaginal discharge. CONCLUSION: This trial does not support the hypothesis that imiquimod, as used in this trial, has an impact on recurrence of cervical dysplasia, but the adequacy of findings are limited by sample size. The trial does support the feasibility and acceptability of the use of imiquimod on the cervix.
Authors: P E Gravitt; C L Peyton; T Q Alessi; C M Wheeler; F Coutlée; A Hildesheim; M H Schiffman; D R Scott; R J Apple Journal: J Clin Microbiol Date: 2000-01 Impact factor: 5.948
Authors: B S Gostout; L C Hartmann; V J Suman; N E Fay; J A Jefferies; R F Morton; T A Gaffey; G H Farr; L K Tschetter; S Abu-Ghazaleh; M M Gallenberg; A K Hatfield Journal: Int J Gynaecol Obstet Date: 2001-08 Impact factor: 3.561
Authors: Annelinde Terlou; Alex Kleinjan; Ilse Beckmann; Claudia Heijmans-Antonissen; Manon van Seters; Lindy A M Santegoets; Marc van Beurden; Theo J M Helmerhorst; Leen J Blok Journal: Int J Cancer Date: 2011-05-15 Impact factor: 7.396
Authors: Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Michael J Thun Journal: CA Cancer J Clin Date: 2007 Jan-Feb Impact factor: 508.702
Authors: Bruno O Fonseca; Júlio C Possati-Resende; Mila P Salcedo; Kathleen M Schmeler; Guilherme S Accorsi; José H T G Fregnani; Marcio Antoniazzi; Naitielle P Pantano; Iara V V Santana; Graziela M Matsushita; Ricardo Dos Reis Journal: Obstet Gynecol Date: 2021-06-01 Impact factor: 7.661
Authors: M M Koeneman; A J Kruse; L F S Kooreman; A Zur Hausen; A H N Hopman; S J S Sep; T Van Gorp; B F M Slangen; H J van Beekhuizen; M van de Sande; C G Gerestein; H W Nijman; R F P M Kruitwagen Journal: BMC Cancer Date: 2016-02-20 Impact factor: 4.430
Authors: Jason R Baird; Zipei Feng; Hong D Xiao; David Friedman; Ben Cottam; Bernard A Fox; Gwen Kramer; Rom S Leidner; R Bryan Bell; Kristina H Young; Marka R Crittenden; Michael J Gough Journal: PLoS One Date: 2017-11-14 Impact factor: 3.240